Updates in Oncology: Oral Presentations from the NCCN Poster Sessions

Target Audience

The program is designed to meet the needs and improve the competence and performance of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals who manage the care of patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Review the results of oncology research as presented in the five top-rated posters.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Abbott's molecular business
  • Adaptive Biotechnologies
  • AstraZeneca
  • BeiGene, Ltd.
  • Blueprint Medicines
  • Daiichi Sankyo
  • Deciphera Pharmaceuticals
  • Eisai
  • Exact Sciences
  • Genentech, a member of the Roche Group
  • Gilead Sciences
  • GlaxoSmithKline
  • GRAIL, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Lilly
  • Olympus Corporation of the Americas
  • Novartis
  • Pfizer
  • Puma Biotechnology
  • Seagen Inc. formerly Seattle Genetics
  • Taiho Oncology, Inc.
  • TeSera Therapeutics

This activity is supported by independent medical education grants from: 

  • Bristol Myers Squibb 
  • Illumina, Inc. 
  • Regeneron Pharmaceuticals, Inc and Sanofi Genzyme

This activity is supported by independent educational grants from:

  • AbbVie
  • Astellas
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Incyte
  • Merck & Co., Inc.

This activity is supported by educational funding provided by Amgen.

This educational activity is supported by a medical education grant from Exelixis, Inc. & Karyopharm® Therapeutics.

This project has been made possible in part by a grant from Varian Medical Systems/Global Medical Education Grant Program.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
05/20/2021
Course expires: 
03/01/2022
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2021 Virtual Annual Conference

Prasanna J. Ananth, MD, MPH
Yale University School of Medicine

Jeremie M.P. Lever, PhD
O'Neal Comprehensive Cancer Center at UAB

Christopher T. Su, MD, MPH
University of Michigan Rogel Cancer Center

Amye J. Tevaarwerk, MD
University of Wisconsin-Madison

Alexandra K. Zaleta, PhD
Cancer Support Community Research and Training Institute

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care.  Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. 

Definitions  

NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.

NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures (Primary Authors and Co-Authors)

The faculty listed below discloses no relevant financial relationships:

Prasanna J. Ananth, MD, MPH
Waddah Arafat, MD
Daniel I. Chu, MD
Kelly A. Clark, MA
Mona N. Fouad, MD, MPH
Ahmer Irfan, MD
Soo Jung Kang, MD, PhD
Jeremie M.P. Lever, PhD
Daniel Martin, MD
Melissa F. Miller, PhD, MPH
Sophia Mun, MPH
Minal R. Patel, PhD, MPH
Sarah Pitafi, NA
Fernanda C. G. Polubriaginof, MD, PhD
Sushanth Reddy, MD
Noora Reffat, MPH
J. Bart Rose, MD
Barry P. Sleckman, MD, PhD
Jeffrey Smerage, MD, PhD
Christopher T. Su, MD, MPH
Amye J. Tevaarwerk, MD
Thomas N. Wang, MD, PhD
Joanne Wolfe, MD, MPH

The faculty listed below discloses the following relevant financial relationships:

Erica E. Fortune, PhD
Boston Scientific Foundation: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

Cary P. Gross, MD
Genentech, Inc.: Grant/Research Support
Johnson and Johnson: Grant/Research Support
Pfizer Inc./AstraZeneca Pharmaceuticals LP: Grant/Research Support 

Elissa C. Kranzler, PhD
Acceleron Pharma, Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
GlaxoSmithKline: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Janssen Pharmaceutica Products, LP /Pharmacyclics: Grant/Research Support
Jazz Pharmaceuticals Inc: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
Xiaomei Ma, PhD
Bristol-Myers Squibb Company: Consulting Fees; Scientific Advisor
Celgene Corporation/Bristol-Myers Squibb Company: Grant/Research Support
Travis Osterman, DO, MS
AstraZeneca Pharmaceuticals LP: Consulting Fees; Scientific Advisor
Biodesix: Consulting Fees; Scientific Advisor
COTA Healthcare: Consulting Fees; Scientific Advisor
eHealth: Consulting Fees; Scientific Advisor
Flagship Biosciences Inc.: Consulting Fees; Scientific Advisor
GE Healthcare: Grant/Research Support
GenomOncology LLC: Consulting Fees; Scientific Advisor
Infostratix, LLC: Equity Interest/Stock Options
MDoutlook: Consulting Fees; Scientific Advisor
Microsoft: Grant/Research Support
Outcomes Insights, Inc: Consulting Fees; Scientific Advisor
Alexandra K. Zaleta, PhD
Astellas Pharma US, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Seagen Inc.: Grant/Research Support

NCCN Staff Disclosures

The NCCN Leadership listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN staff listed below disclose no relevant financial relationships:

Nicole A. Kamienski, BS, CCRP

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-21-084-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 1, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing